<DOC>
	<DOC>NCT01210391</DOC>
	<brief_summary>The primary objective of the clinical trial is to compare growth in infants (expressed as weight gain in g/day) consuming a new extensively hydrolyzed formula (EHF) to infants consuming a commercially available EHF.</brief_summary>
	<brief_title>Growth of Infants Fed an Extensively Hydrolyzed Infant Formula</brief_title>
	<detailed_description />
	<criteria>Healthy newborn singleton infant Fullterm (&gt;= 37 weeks gestation) Birth weight between &gt;= 2500 and &lt; =4500 g 14 Â± 3 days of age on enrollment Infant's mother has elected not to breastfeed baby has been exclusively formula fed a minimum of 3 days prior to enrollment Study explained and written information provided with Parent/Caregiver Informed consent signed (parent/legal representative) Congenital illness or malformation affecting infant feeding and/or growth Suspected or known allergy to cow's milk protein Significant prenatal and/or postnatal disease Any readmission to hospital (except for hyperbilirubinemia) prior to enrollment Infant has received oral or IV antibiotic therapy in the 10 days prior to enrollment Infant receiving prescription medication (with exception of topical antibiotics and/or treatment for thrush) or frequent use of over the counter medications except vitamin and mineral supplements Infant has received probiotics in the seven days prior to enrollment Infant currently participating in another clinical study Infant's family who in the Investigator's assessment cannot be expected to comply with the protocol</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>4 Months</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>